Rosalind Advisors Inc. Lowers Position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)

Rosalind Advisors Inc. lowered its stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,555 shares of the company’s stock after selling 5,000 shares during the period. Kiora Pharmaceuticals makes up approximately 0.4% of Rosalind Advisors Inc.’s portfolio, making the stock its 25th biggest holding. Rosalind Advisors Inc. owned approximately 8.35% of Kiora Pharmaceuticals worth $827,000 at the end of the most recent reporting period.

Kiora Pharmaceuticals Stock Performance

KPRX stock opened at $3.29 on Friday. The business has a fifty day simple moving average of $3.51 and a 200-day simple moving average of $3.49. Kiora Pharmaceuticals, Inc. has a 52 week low of $2.91 and a 52 week high of $6.48.

Kiora Pharmaceuticals Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.